Immunotherapies targeting CD38 in Multiple Myeloma

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Oncoimmunology

• Publication date

  2016-08-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/2162402X.2016.1217374PMID 27999737PMCID PMC5139636
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma.

  2016cited by this paper
• Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

  2016cited by this paper
• Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

  2015cited by this paper
• Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide.

  2015cited by this paper
• Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard‐risk cytogenetics

  2015cited by this paper
• NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

  2015influential reference
• Re‐challenging with anti‐CD38 monotherapy in triple‐refractory multiple myeloma patients is a feasible and safe approach

  2015cited by this paper
• Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

  2015cited by this paper
• Phase II study of daratumumab (DARA) monotherapy in patients with ≥ 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius).

  2015cited by this paper
• Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma

  2015cited by this paper
• A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM).

  2015cited by this paper
• Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab

  2015cited by this paper
• Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy

  2015cited by this paper
• Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.

  2015cited by this paper
• A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture

  2015influential reference
• Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

  2015cited by this paper
• Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

  2015cited by this paper
• SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

  2015cited by this paper
• Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

  2015cited by this paper
• Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79

  2014influential reference
• α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma

  2014cited by this paper
• SAR 650984, a Therapeutic Anti-CD38 Monoclonal Antibody, Blocks CD38-CD31 Interaction in Multiple Myeloma

  2014cited by this paper
• SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

  2014influential reference
• A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

  2014cited by this paper
• A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

  2014cited by this paper
• Synergistic in Vitro Activity of MOR202, a Human CD38 Antibody, in Combination with Pomalidomide

  2014cited by this paper
• A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

  2014cited by this paper
• Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival

  2014cited by this paper
• Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

  2014cited by this paper
• Exosome complex and erythropoiesis.

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• It takes a village.

  2014cited by this paper
• Immunotherapy with Long-Lived Anti-CD38 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human Myeloma Cell Lines and CD38+ Cells in Monkeys: A Potential Therapy for Multiple Myeloma

  2014cited by this paper
• Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.

  2013cited by this paper
• SAR650984, a CD38 Monoclonal Antibody In Patients With Selected CD38+ Hematological Malignancies- Data From a Dose-Escalation Phase I Study

  2013cited by this paper
• Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma.

  2012cited by this paper
• CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype

  2012cited by this paper
• T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1

  2012cited by this paper
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

  2012cited by this paper
• Antigenic drift in relapsed extramedullary multiple myeloma: plasma cells without CD38 expression

  2012cited by this paper
• The homeodomain region controls the phenotype of HOX-induced murine leukemia.

  2012cited by this paper
• High Levels of Peripheral Blood Circulating Plasma Cells as a Specific Risk Factor for Progression of Smoldering Multiple Myeloma

  2012cited by this paper
• The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo

  2012cited by this paper
• CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients

  2012cited by this paper
• Autologous stem cell transplantation and multiple myeloma cancer stem cells.

  2012cited by this paper
• Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma

  2012cited by this paper
• CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells

  2012cited by this paper
• Multiple myeloma.

  2011cited by this paper
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

  2011cited by this paper
• Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

  2011influential reference
• Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

  2011cited by this paper
• T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells

  2011cited by this paper
• Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.

  2010cited by this paper
• Primary plasma cell leukaemia: immunological and ultrastructural studies in 6 cases.

  2009cited by this paper
• Activated T–cell-mediated Immunotherapy With a Chimeric Receptor Against CD38 in B-cell Non-Hodgkin Lymphoma

  2009cited by this paper
• Myelomatous pleural effusion in a patient with plasmablastic myeloma: A case report

  2009influential reference
• Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease

  2009cited by this paper
• Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study

  2008cited by this paper
• Solitary pleural plasmacytomas manifested as a massive pleural effusion without evidence of monoclonal gammopathy

  2008cited by this paper
• Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

  2008cited by this paper
• Immunophenotypic studies of monoclonal gammopathy of undetermined significance

  2008cited by this paper
• CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia.

  2005cited by this paper
• Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.

  2005cited by this paper
• Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma.

  2005cited by this paper
• Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment

  2005cited by this paper
• Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells.

  2004cited by this paper
• Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.

  2003cited by this paper
• Human myeloma cells express the CD38 ligand CD31

  1999cited by this paper
• Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.

  1999cited by this paper
• Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member.

  1998cited by this paper
• Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

  1998cited by this paper
• Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59

  1997cited by this paper
• Secretion of IFN-gamma, IL-6, granulocyte-macrophage colony-stimulating factor and IL-10 cytokines after activation of human purified T lymphocytes upon CD38 ligation.

  1996influential reference
• Identification of early plasma cells in peripheral blood and their clinical significance

  1996cited by this paper
• Human CD38, a cell‐surface protein with multiple functions

  1996cited by this paper
• CD38 signal transduction in human B cell precursors. Rapid induction of tyrosine phosphorylation, activation of syk tyrosine kinase, and phosphorylation of phospholipase C-gamma and phosphatidylinositol 3-kinase.

  1996cited by this paper
• Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids.

  1996cited by this paper
• In Multiple Myeloma, Clonotypic B Lymphocytes Are Detectable Among CD19+ Peripheral Blood Cells Expressing CD38, CD56, and Monotypic Ig Light Chain

  1995cited by this paper
• Ligation of CD38 suppresses human B lymphopoiesis

  1995cited by this paper
• Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.

  1995cited by this paper
• In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.

  1995cited by this paper
• Evaluation of CD38 as target for immunotherapy in multiple myeloma.

  1995cited by this paper
• CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.

  1995cited by this paper
• Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma.

  1995influential reference
• Assignment of CD38, the gene encoding human leukocyte antigen CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase), to chromosome 4p15.

  1995cited by this paper
• Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma.

  1994influential reference
• Cell surface markers in multiple myeloma.

  1994cited by this paper
• CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells

  1994cited by this paper
• A B lymphocyte surface molecule mediating activation and protection from apoptosis via calcium channels.

  1993cited by this paper
• Identification of immature and mature myeloma cells in the bone marrow of human myelomas.

  1993cited by this paper
• Phenotypic difference of normal plasma cells from mature myeloma cells.

  1993cited by this paper
• Extramedullary plasmacytoma: cytological and genotypic studies

  1993cited by this paper
• Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38.

  1993cited by this paper
• Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules.

  1992cited by this paper
• Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells

  1992influential reference
• Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease

  1991cited by this paper
• Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.

  1991influential reference
• Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry.

  1990cited by this paper
• Analysis of surface antigen expression of human immunoglobulin‐secreting cells: phenotypic heterogeneity in normal counterparts of myeloma cells

  1989cited by this paper
• An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd International Workshop on Human Leucocyte Differentiation Antigens.

  1988cited by this paper

• Development of a Selective and Potent PRMT4 PROTAC Degrader with Efficacy against Multiple Myeloma in Vitro and in Vivo.

  2025cites this paper
• Affinity Peptides With pH Sensitivity for the Enrichment of CD38+ Cells.

  2025cites this paper
• CAR-NK cells for haematological cancers.

  2025cites this paper
• CD38 Targeting Holds Potential for the Treatment of Aggressive Refractory Cutaneous T-Cell Lymphomas.

  2023cites this paper
• A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma

  2023cites this paper
• Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA.

  2022cites this paper
• Anti-cancer activity of Biochanin A against multiple myeloma by targeting the CD38 and cancer stem-like cells

  2022cites this paper
• Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients

  2022cites this paper
• Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma: subgroup analysis of the randomized, open label, phase 3 IKEMA study

  2022cites this paper
• B cell-targeted therapies in systemic lupus erythematosus.

  2022cites this paper
• Expanding anti-CD38 immunotherapy for lymphoid malignancies

  2022cites this paper
• High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma

  2022cites this paper
• Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.

  2021cites this paper
• CD38-Directed Therapies for Management of Multiple Myeloma

  2021cites this paper
• A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma

  2021cites this paper
• Polymeric nanomedicines targeting hematological malignancies.

  2021cites this paper
• Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

  2020cites this paper
• Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies

  2020cites this paper
• CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers

  2020cites this paper
• CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity

  2020cites this paper
• Anti-body building: The exercise of advancing immune based myeloma therapies.

  2020cites this paper
• Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.

  2019cites this paper
• Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.

  2019cites this paper
• CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents

  2019cites this paper
• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

  2019cites this paper
• CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

  2018cites this paper
• Új kezelési lehetőség – új probléma? Miért interferál a daratumumab a vércsoport-szerológiai vizsgálatokkal?

  2018cites this paper
• CD38 as an immunotherapeutic target in multiple myeloma

  2018cites this paper
• Identification of key genes in prostate cancer gene expression profile by bioinformatics

  2018cites this paper
• Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

  2018cites this paper
• Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies

  2018cites this paper
• NAD Metabolism in Cancer Therapeutics

  2018cites this paper
• Trial watch: Peptide-based vaccines in anticancer therapy

  2018cites this paper
• Therapy of Multiple Myeloma and Myeloma-Related Kidney Disease

  2017cites this paper
• Myeloma; living better and living longer - a look at the advances

  2017cites this paper
• Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

  2017cites this paper
• Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection

  2017cites this paper